Skip to main content
Premium Trial:

Request an Annual Quote

Access Inks Delivery Technology-Evaluation Deal with Undisclosed Pharma

Premium

Access Pharmaceuticals this week announced that it has signed a deal under which its CobaCyte and CobOral siRNA delivery technologies will be evaluated by an undisclosed pharmaceutical company.

The delivery approaches are based on Access' so-called Cobalamin technology, which takes advantage of the body's natural vitamin B12-uptake mechanism. A polymer and an siRNA are joined to make a nanoparticle, which is then coated with the vitamin.

According to Access, it will provide oral and intravenous siRNA formulations to the pharmaceutical firm for evaluation.

Successfully developed compounds will be subject to a formal licensing agreement, Access noted.

Additional terms were not disclosed. The deal follows a similar arrangement Access forged earlier in the year (GSN 4/14/2011).

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.